Dr. Stanislav Glezer M.D., MBA Net Worth

The estimated Net Worth of Stanislav Glezer is at least $1.19 Million dollars as of 1 May 2024. Dr Glezer owns over 32,638 units of Inogen Inc stock worth over $563,481 and over the last 3 years he sold INGN stock worth over $0. In addition, he makes $628,300 as Exec. VP & CTO at Inogen Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Dr MBA INGN stock SEC Form 4 insiders trading

Dr has made over 8 trades of the Inogen Inc stock since 2022, according to the Form 4 filled with the SEC. Most recently he exercised 32,638 units of INGN stock worth $377,295 on 1 May 2024.

The largest trade he's ever made was exercising 32,638 units of Inogen Inc stock on 1 May 2024 worth over $377,295. On average, Dr trades about 5,894 units every 55 days since 2021. As of 1 May 2024 he still owns at least 48,744 units of Inogen Inc stock.

You can see the complete history of Dr Glezer stock trades at the bottom of the page.

Dr. Stanislav Glezer M.D., MBA biography

Dr. Stanislav Glezer M.D., MBA is the Exec. VP & CTO at Inogen Inc.

What is the salary of Dr MBA?

As the Exec. VP & CTO of Inogen Inc, the total compensation of Dr MBA at Inogen Inc is $628,300. There are 5 executives at Inogen Inc getting paid more, with Scott Wilkinson having the highest compensation of $2,520,530.

How old is Dr MBA?

Dr MBA is 48, he's been the Exec. VP & CTO of Inogen Inc since . There are 15 older and 4 younger executives at Inogen Inc. The oldest executive at Inogen Inc is Benjamin Anderson-Ray, 65, who is the Independent Director.

What's Dr MBA's mailing address?

Stanislav's mailing address filed with the SEC is C/O INOGEN, INC., 859 WARD DRIVE, GOLETA, CA, 93111.

Insiders trading at Inogen Inc

Over the last 11 years, insiders at Inogen Inc have traded over $242,179,025 worth of Inogen Inc stock and bought 9,125 units worth $253,950 . The most active insiders traders include Holdings A/S Novo, Timothy Petersen, and Raymond Huggenberger. On average, Inogen Inc executives and independent directors trade stock every 10 days with the average trade being worth of $321,391. The most recent stock trade was executed by Jason Somer on 1 June 2024, trading 577 units of INGN stock currently worth $6,670.

What does Inogen Inc do?

inogen’s mission to improve the quality of life of supplemental oxygen users began in 2001 when mae, a beloved grandmother, was prescribed oxygen therapy. learn more about mae’s story here: http://www.inogen.com/about-inogen/meet-mae/. inogen was founded based on our conviction that oxygen therapy technology was not keeping pace with the desired lifestyles of patients who depended on it to live longer, more fulfilling lives. we estimate that more than 2.5 million patients in the united states and more than 4.5 million patients worldwide use oxygen therapy. our compact, lightweight and travel-approved portable oxygen concentrators are designed to free patients from heavy tanks, managing tank refills or being tethered to stationary systems. we believe our products allow oxygen therapy patients to reclaim their freedom and independence so that life can be lived in moments, not in minutes left in an oxygen tank. with each step we take to improve our products and service, our customers take

Complete history of Dr Glezer stock trades at Inogen Inc

Inogen Inc executives and stock owners

Inogen Inc executives and other stock owners filed with the SEC include:

• Scott Wilkinson,
  President, Chief Executive Officer, Director
• Alison Bauerlein,
  Executive Vice President - Finance and Chief Financial Officer, Corporate Secretary and Corporate Treasurer
• Bart Sanford,
  Executive Vice President, Operations
• Byron Myers,
  Executive Vice President of Marketing
• Brenton Taylor,
  Executive Vice President - Engineering
• Dr. Stanislav Glezer M.D., MBA,
  Exec. VP & CTO
• Alison Perry Bauerlein,
  Co-Founder
• Bart Sanford,
  Exec. VP of Operations
• Heath Lukatch,
  Independent Chairman of the Board
• Heather Rider,
  Independent Director
• R. Scott Greer,
  Independent Director
• Loren McFarland,
  Independent Director
• Benjamin Anderson-Ray,
  Independent Director
• Raymond Huggenberger,
  Independent Director
• Matt Bacso,
  IR Contact Officer
• Scott Beardsley,
  Independent Director
• Arron Retterer,
  Executive Vice President of Sales
• Jennifer Yi Boyer,
  Exec. VP & Chief HR Officer
• Agnes Lee,
  Sr. VP of Investor Relations & Strategic Planning
• Kristin A. Caltrider,
  Exec. VP, CFO & Treasurer
• Matthew Pigeon,
  Investor Relations Officer
• George J. Parr,
  Exec. VP & Chief Commercial Officer
• Jason Somer,
  Exec. VP, Gen. Counsel & Corp. Sec.
• Matthew James Bacso C.F.A.,
  Investor Relations & Corp. Devel. Mang.
• Michael K. Sergesketter,
  Interim Chief Financial Officer
• Nabil Shabshab,
  CEO, Pres & Director
• Kevin M King,
  
• Matt Scribner,
  See Remarks
• George J Parr,
  Chief Commercial Officer
• William J Phd Link,
  Director
• Ventures Ii Llc Versant Ven...,
  
• Kristin A. Caltrider,
  EVP, CFO and Treasurer
• Ventures Ii Llc Versant Ven...,
  
• Ventures Ii Llclink William...,
  
• Ventures Ii Lp Arboretum Ve...,
  
• Stephen E. Cooper,
  Director
• Ventures Ii Llc Versant Ven...,
  
• Ventures Ii Llc Versant Ven...,
  
• Ventures Ii Llc Versant Ven...,
  
• Holdings A/S Novo,
  10% owner
• Charles E Larsen,
  Director
• Timothy Petersen,
  Director
• Ventures Ii Llc Versant Ven...,
  
• Kevin Raymond Merrill Smith,
  CEO and President
• Kristen Miranda,
  Director
• Nabil Shabshab,
  CEO and President
• Stanislav Glezer,
  EVP, R&D & Chief Med. Officer
• Jason Somer,
  EVP, Gen. Counsel & Secretary
• Michael J. Bourque,
  EVP, CFO & Treasurer
• Elizabeth Mora,
  
• Thomas A. West,
  
• Mary Kay Ladone,
  
• Glenn S Boehnlein,
  
• Kevin P. Smith,
  EVP, Bus Dev, GC & Sec